Cargando…
Systemic Sclerosis Association with Malignancy
The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc cli...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674744/ https://www.ncbi.nlm.nih.gov/pubmed/36121543 http://dx.doi.org/10.1007/s12016-022-08930-4 |
_version_ | 1784833217839235072 |
---|---|
author | Lepri, Gemma Catalano, Martina Bellando-Randone, Silvia Pillozzi, Serena Giommoni, Elisa Giorgione, Roberta Botteri, Cristina Matucci-Cerinic, Marco Antonuzzo, Lorenzo Guiducci, Serena |
author_facet | Lepri, Gemma Catalano, Martina Bellando-Randone, Silvia Pillozzi, Serena Giommoni, Elisa Giorgione, Roberta Botteri, Cristina Matucci-Cerinic, Marco Antonuzzo, Lorenzo Guiducci, Serena |
author_sort | Lepri, Gemma |
collection | PubMed |
description | The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc clinical and serological features identify patients at major risk to develop malignancy. In this context, among serological features, presence of anti-RNA polymerase III and anti-topoisomerase I autoantibodies seems to increase cancer frequency in SSc patients (particularly lung and breast cancers). Lung fibrosis and a long standing SSc pulmonary involvement have been largely proposed as lung cancer risk factors, and the exposure to cyclophosphamide and an upper gastrointestinal involvement have been traditionally linked to bladder and oesophagus cancers, respectively. Furthermore, immune checkpoint inhibitors used for cancer therapy can induce immune-related adverse events, which are more frequent and severe in patients with pre-existing autoimmune diseases such as SSc. The strong association between SSc and cancer occurrence steers clinicians to carefully survey SSc patients performing periodical malignancy screening. In the present review, the most relevant bilateral relationships between SSc and cancer will be addressed. |
format | Online Article Text |
id | pubmed-9674744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-96747442022-11-20 Systemic Sclerosis Association with Malignancy Lepri, Gemma Catalano, Martina Bellando-Randone, Silvia Pillozzi, Serena Giommoni, Elisa Giorgione, Roberta Botteri, Cristina Matucci-Cerinic, Marco Antonuzzo, Lorenzo Guiducci, Serena Clin Rev Allergy Immunol Article The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc clinical and serological features identify patients at major risk to develop malignancy. In this context, among serological features, presence of anti-RNA polymerase III and anti-topoisomerase I autoantibodies seems to increase cancer frequency in SSc patients (particularly lung and breast cancers). Lung fibrosis and a long standing SSc pulmonary involvement have been largely proposed as lung cancer risk factors, and the exposure to cyclophosphamide and an upper gastrointestinal involvement have been traditionally linked to bladder and oesophagus cancers, respectively. Furthermore, immune checkpoint inhibitors used for cancer therapy can induce immune-related adverse events, which are more frequent and severe in patients with pre-existing autoimmune diseases such as SSc. The strong association between SSc and cancer occurrence steers clinicians to carefully survey SSc patients performing periodical malignancy screening. In the present review, the most relevant bilateral relationships between SSc and cancer will be addressed. Springer US 2022-09-19 2022 /pmc/articles/PMC9674744/ /pubmed/36121543 http://dx.doi.org/10.1007/s12016-022-08930-4 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lepri, Gemma Catalano, Martina Bellando-Randone, Silvia Pillozzi, Serena Giommoni, Elisa Giorgione, Roberta Botteri, Cristina Matucci-Cerinic, Marco Antonuzzo, Lorenzo Guiducci, Serena Systemic Sclerosis Association with Malignancy |
title | Systemic Sclerosis Association with Malignancy |
title_full | Systemic Sclerosis Association with Malignancy |
title_fullStr | Systemic Sclerosis Association with Malignancy |
title_full_unstemmed | Systemic Sclerosis Association with Malignancy |
title_short | Systemic Sclerosis Association with Malignancy |
title_sort | systemic sclerosis association with malignancy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674744/ https://www.ncbi.nlm.nih.gov/pubmed/36121543 http://dx.doi.org/10.1007/s12016-022-08930-4 |
work_keys_str_mv | AT leprigemma systemicsclerosisassociationwithmalignancy AT catalanomartina systemicsclerosisassociationwithmalignancy AT bellandorandonesilvia systemicsclerosisassociationwithmalignancy AT pillozziserena systemicsclerosisassociationwithmalignancy AT giommonielisa systemicsclerosisassociationwithmalignancy AT giorgioneroberta systemicsclerosisassociationwithmalignancy AT bottericristina systemicsclerosisassociationwithmalignancy AT matuccicerinicmarco systemicsclerosisassociationwithmalignancy AT antonuzzolorenzo systemicsclerosisassociationwithmalignancy AT guiducciserena systemicsclerosisassociationwithmalignancy |